Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences, Inc. (Nasdaq: GILD) is a Delaware‑incorporated biopharmaceutical company whose common stock is registered on The Nasdaq Global Select Market. As an SEC‑reporting issuer, Gilead files a range of regulatory documents that provide detailed insight into its financial condition, governance and material events. This page aggregates GILD’s SEC filings and pairs them with AI‑generated summaries to help readers understand the key points in complex disclosures.
For Gilead, Form 10‑K annual reports and Form 10‑Q quarterly reports are central sources of information on its HIV, viral hepatitis, COVID‑19, oncology and inflammation businesses, including segment discussions, risk factors and research and development spending. Form 8‑K current reports capture specific developments such as quarterly financial results, amendments to bylaws, executive leadership changes and significant agreements. Recent 8‑K filings, for example, have disclosed financial results for particular quarters, updates to the company’s bylaws governing director nominations and stockholder proposals, patent settlements related to Biktarvy, and changes in senior corporate affairs and legal roles.
Investors can also use this page to access proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports to track trades by directors and officers. Because Gilead is not classified as an emerging growth company, its filings follow the full disclosure requirements applicable to large, established issuers.
Stock Titan enhances GILD filings with AI‑powered explanations that highlight material items, translate technical accounting and legal language into plain terms, and surface topics such as governance changes, litigation updates or collaboration agreements. Real‑time ingestion from EDGAR means new Gilead filings appear quickly, while the AI layer helps readers focus on what changed, why it matters for the company’s HIV, antiviral and oncology franchises, and how it may affect shareholders.
Gilead Sciences Chief Financial Officer Andrew Dickinson reported routine equity compensation activity. On March 10, 2026, he exercised restricted stock units into 6,469 shares of common stock and received a new grant of 9,590 restricted stock units, each representing one future share.
He was also granted 35,880 non-qualified stock options with an exercise price of $148.56 per share, expiring on March 10, 2036. Following the RSU exercise, 3,147 shares of common stock were withheld to cover tax obligations, leaving him with 182,191 common shares and 30,647 restricted stock units directly owned.
The RSU and option grants vest over four years, with 25% vesting on the first anniversary of the grant and the remaining 75% vesting in 6.25% quarterly installments, aligning his compensation with long-term shareholder value.
Gilead Sciences’ Chief Comm & Corp Aff Officer Johanna Mercier reported routine equity compensation activity. She exercised 6,617 restricted stock units into the same number of common shares, with 3,216 shares withheld at a price of 148.5600 per share to cover tax obligations, leaving her with 134,779 common shares held directly.
Mercier also received new awards: 9,590 restricted stock units and 35,880 non-qualified stock options exercisable at 148.5600 per share and expiring on March 10, 2036. Both the RSUs and options vest over four years, with 25% vesting after one year and the remainder vesting 6.25% quarterly.
Gilead Sciences EVP Keeley M Cain Wettan reported routine equity compensation changes. On March 10, 2026, 1,246 restricted stock units converted into the same number of common shares, increasing her direct common stock holdings to 5,054 shares after 606 shares were withheld to cover taxes.
She also received 5,050 new restricted stock units and 18,885 non-qualified stock options exercisable at $148.56 per share, expiring in 2036. Both the RSUs and options vest over four years, with 25% vesting after one year and the remainder vesting quarterly at 6.25% until fully vested.
Gilead Sciences SVP receives new equity awards. Senior Vice President of Controllership Erin Burkhart was granted 2,355 restricted stock units and 5,455 non-qualified stock options, each tied to Gilead common stock. Both awards have a four-year vesting schedule, with 25% vesting after one year and the remainder vesting quarterly. Following the grant, Burkhart directly holds 11,245 restricted stock units and 5,455 stock options with a $148.56 exercise price, providing long-term, performance-linked compensation rather than immediate market purchases or sales.
Gilead Sciences Chairman & CEO Daniel O'Day reported routine equity compensation changes. He exercised 20,026 restricted stock units into the same number of common shares, with 9,767 shares withheld to cover tax obligations, leaving him with 652,567 common shares held directly.
O'Day also received new equity awards: 32,815 restricted stock units and 122,755 non-qualified stock options exercisable at $148.56 per share and expiring on March 10, 2036. Both the RSUs and options vest over four years, with 25% vesting after one year and the remainder vesting 6.25% quarterly until fully vested.
Gilead Sciences Chief Medical Officer Dietmar Berger reported multiple equity compensation transactions. He exercised 2,133 restricted stock units into common shares, with 1,063 of those shares withheld at $148.56 per share to cover tax obligations rather than sold on the market.
Berger also received 8,415 new restricted stock units and a grant of 31,475 non-qualified stock options exercisable at $148.56 per share, expiring on March 10, 2036. Following these events, he directly holds 18,982 shares of common stock and 47,461 restricted stock units, all subject to multi-year vesting schedules.
Gilead Sciences, through its wholly owned subsidiary Ravens Sub, Inc., is offering to acquire Arcellx, Inc. by purchasing all outstanding common shares at $115.00 per share in cash plus one contingent value right (CVR) that can pay $5.00 on March 31, 2030 if cumulative worldwide sales of anito-cel exceed $6.0 billion on or prior to December 31, 2029.
The Schedule TO states 58,672,448 shares were outstanding as of March 3, 2026, and the Offer is not subject to a financing condition. The merger agreement and offer documents are filed as exhibits.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson acquired 11,090 shares of common stock through a grant/award on performance share units. These shares vested after both performance and service conditions were met, bringing his directly held total to 178,869 shares of Gilead common stock.
Mercier Johanna reported acquisition or exercise transactions in this Form 4 filing.
Gilead Sciences executive Johanna Mercier received 11,090 shares of common stock through the vesting of performance share award tranches. These shares relate to awards granted on March 10, 2025 that carried both performance- and service-vesting conditions. After this award, her directly held common stock totals 131,378 shares.
Gilead Sciences Chief Medical Officer Dietmar Berger acquired 8,530 shares of common stock at no cost through a grant/award transaction. These shares relate to specific tranches of performance share awards originally granted on March 10, 2025.
The performance-vesting requirement for these tranches was satisfied on February 27, 2026, when the Compensation and Talent Committee certified that the performance goals were met. Following this award, Berger directly holds a total of 17,912 Gilead common shares.